Alterola Biotech, Inc.
ABTI · OTC
3/31/2023 | 3/31/2022 | 9/30/2020 | 9/30/2019 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.30 | -0.06 | 15.36 | -6.60 |
| FCF Yield | -3.35% | 0.03% | 0.00% | 0.00% |
| EV / EBITDA | -21.59 | -26.19 | -334.62 | -550.22 |
| Quality | ||||
| ROIC | -14.98% | -58.35% | 69.80% | 127.50% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.60 | -0.01 | – | – |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -2,760.09% | 0.00% | 0.00% | 100.00% |
| Safety | ||||
| Net Debt / EBITDA | -0.83 | -0.02 | 0.00 | 0.00 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | -1,037.96 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |